Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
HK1238545A1 - Combination therapies - Google Patents
[go: Go Back, main page]

HK1238545A1 - Combination therapies - Google Patents

Combination therapies Download PDF

Info

Publication number
HK1238545A1
HK1238545A1 HK17112501.8A HK17112501A HK1238545A1 HK 1238545 A1 HK1238545 A1 HK 1238545A1 HK 17112501 A HK17112501 A HK 17112501A HK 1238545 A1 HK1238545 A1 HK 1238545A1
Authority
HK
Hong Kong
Prior art keywords
combination therapies
therapy
effective amount
antagonizes
taxane
Prior art date
Application number
HK17112501.8A
Other languages
Chinese (zh)
Inventor
雷恩施乐 马库斯
阿勒斯 马克
Original Assignee
细胞基因公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 细胞基因公司 filed Critical 细胞基因公司
Publication of HK1238545A1 publication Critical patent/HK1238545A1/en

Links

Abstract

The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that antagonizes a PD-1 pathway in a cell.
HK17112501.8A 2014-12-02 2015-12-01 Combination therapies HK1238545A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62/086,533 2014-12-02

Publications (1)

Publication Number Publication Date
HK1238545A1 true HK1238545A1 (en) 2018-05-04

Family

ID=

Similar Documents

Publication Publication Date Title
MX2017007321A (en) Combination therapies.
MY166014A (en) Combination therapy methods for treating proliferative diseases
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
WO2014194254A9 (en) Treatment of cancers using pi3 kinase isoform modulators
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
CA2956871C (en) Compounds active towards bromodomains
MX387885B (en) Ezh2 inhibitors for treating lymphoma
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
NZ719049A (en) Cancer treatment with combination of plinabulin and taxane
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
MX2015011752A (en) Methods of treating lung cancer.
HK1219231A1 (en) Methods of treatment of pediatric solid tumor
WO2016100738A3 (en) Antifibrotic activity of gas6 inhibitor
MX386613B (en) Treatment of cancer with immune stimulators
EA201591925A1 (en) THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
PH12016501527B1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
WO2015159155A3 (en) Novel ademetionine formulations
HK1253098A1 (en) Dosage regimen of mdm2 inhibitor for treating cancers
WO2016130581A3 (en) Combination cancer therapy
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
WO2017079403A3 (en) Polymeric nanoparticles
WO2014153643A8 (en) Compositions and methods for use thereof in the treatment of aniridia
HK1238545A1 (en) Combination therapies
MX2021001081A (en) Combination therapy for treating cancer.